VDyne has announced the appointment of Mike Buck as chairman and CEO, leading the company’s efforts to bring to market its transcatheter tricuspid valve replacement (TTVR) system to treat tricuspid regurgitation.
Buck brings more than 30 years of leadership experience in cardiovascular medical technology. Most recently, he served as CEO of Verge Medical and previously was founder and CEO of TRUVIC Medical (acquired by Imperative Care). Earlier in his career, he served as president of Cardinal Health’s medical products division and held senior leadership roles at Abbott, including corporate vice president and global commercial leader for Abbott’s Vascular business, as well as leading Abbott’s global Licensing and Acquisitions function.
VDyne has conducted clinical studies across 15 countries, with more than 100 successful TTVR procedures to date. The company has received US Food and Drug Administration (FDA) breakthrough device designation and is advancing toward CE marking and initiation of its US pivotal clinical study, positioning VDyne among companies advancing next-generation TTVR therapies.
“VDyne has built a strong clinical foundation, and the opportunity to improve the lives of patients with tricuspid regurgitation is significant. I look forward to working alongside this team as we advance the technology and continue building the clinical evidence behind it,” said Buck.
“Mike brings deep experience in structural heart and a proven ability to build and lead strong teams. As VDyne advances its clinical programs, his leadership will be critical in guiding the company through its next phase,” said Greg Pearl, VDyne board member.
